The phase 2 VIKTORY umbrella trial showed that in patients with metastatic and/or recurrent gastric adenocarcinoma, savolitinib monotherapy had an ORR of 50% (10/20) in the subset of gastric cancer patients with MET amplification. This evidence concerns the gene MET and gastric cancer.